{"id":"86b88df764bd","type":"article","url":"https://hartvaat.nl/2016/08/07/il-6-receptorantagonist-tocilizumab-bij-nstemi-effect-op-inflammatie-en-troponin/","title":"IL-6-receptorantagonist tocilizumab bij NSTEMI: effect op inflammatie en troponine","title_en":"Effect of a single dose of the interleukin-6 receptor antagonist tocilizumab on inflammation and troponin T release in patients with non-ST-elevation myocardial infarction: a double-blind, randomized, placebo-controlled phase 2 trial.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":["inflammatie"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehw171","source_url":"https://doi.org/10.1093/eurheartj/ehw171","authors":["Ola Kleveland","Gabor Kunszt","Marte Bratlie","Thor Ueland","Kaspar Broch","Espen Holte","Annika E Michelsen","Bjørn Bendz","Brage H Amundsen","Terje Espevik","Svend Aakhus","Jan Kristian Damås","Pål Aukrust","Rune Wiseth","Lars Gullestad"],"significance":7,"published":"2016-08-07","source_date":"2016-08-07","image":"","kennis":["https://hartvaat.nl/kennis/diagnostiek/cardiale-biomarkers-overzicht/","https://hartvaat.nl/kennis/coronairlijden/wat-is-coronairlijden/"],"congress":"","summary_en":"This study showed that a single dose of tocilizumab, an IL-6 receptor antagonist, significantly reduced inflammation markers and attenuated troponin T release in patients with acute STEMI, providing proof-of-concept for targeted anti-inflammatory therapy in acute MI.","created":"2026-07-03T10:26:16Z","updated":"2026-07-03T13:25:36Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Studie die het effect onderzocht van een enkele dosis tocilizumab, een IL-6-receptorantagonist, op inflammatiemarkers en troponine T bij NSTEMI. Mechanistisch bewijs voor de inflammatiehypothese bij acuut coronair syndroom.","abstract_original":"AIMS: Interleukin-6 (IL-6) contributes to atherosclerotic plaque destabilization and is involved in myocardial injury during ischaemia-reperfusion. Interleukin-6 is therefore a potential therapeutic target in myocardial infarction (MI). We hypothesized that the IL-6 receptor antagonist tocilizumab would attenuate inflammation, and secondarily reduce troponin T (TnT) release in non-ST-elevation MI (NSTEMI). METHODS AND RESULTS: In a two-centre, double-blind, placebo-controlled trial, 117 patients with NSTEMI were randomized at a median of 2 days after symptom onset to receive placebo (n = 59) or tocilizumab (n = 58), administered as a single dose prior to coronary angiography. High sensitivity (hs) C-reactive protein and hsTnT were measured at seven consecutive timepoints between Days 1 and 3. The area under the curve (AUC) for high-sensitivity C-reactive protein was the primary endpoint. The median AUC for high-sensitivity C-reactive protein during hospitalization was 2.1 times higher in the placebo than in the tocilizumab group (4.2 vs. 2.0 mg/L/h, P < 0.001). Also, the median AUC for hsTnT during hospitalization was 1.5 times higher in the placebo group compared with the tocilizumab group (234 vs. 159 ng/L/h, P = 0.007). The differences between the two treatment groups were observed mainly in (i) patients included ≤2 days from symptom onset and (ii) patients treated with percutaneous coronary intervention (PCI). No safety issues in the tocilizumab group were detected during 6 months of follow-up. CONCLUSION: Tocilizumab attenuated the inflammatory response and primarily PCI-related TnT release in NSTEMI patients."}